Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Max Flu Strength is a combination small molecule pharmaceutical product developed and manufactured by Bristol Laboratories for the symptomatic relief of cold and flu. It contains two active ingredients: paracetamol (acetaminophen) and phenylephrine hydrochloride. Paracetamol serves as a non-salicylate analgesic and antipyretic, primarily acting through the inhibition of prostaglandin synthesis in the central nervous system to alleviate pain and reduce fever. Phenylephrine is a sympathomimetic amine that acts as a selective alpha-1 adrenergic receptor agonist, inducing vasoconstriction in the nasal mucosa to relieve congestion. The product is approved for the relief of aches, pains, headache, nasal congestion, and sore throat associated with influenza and the common cold.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + phenylephrine (Bristol Laboratories).